ICU Medical (NASDAQ:ICUI) Stock Price Expected to Rise, Piper Sandler Analyst Says

Key Points

• Piper Sandler analysts raised ICU Medical's price target from $145.00 to $153.00, indicating a potential upside of 17.18%.
• ICU Medical reported earnings of $2.10 per share for the last quarter, exceeding estimates by $0.66, but experienced an 8.0% decline in year-over-year revenue.
• Insider transactions show significant purchases, with CEO Vivek Jain acquiring 21,929 shares at an average price of $112.84, boosting his holdings by 20.26%.

ICU Medical (NASDAQ:ICUI - Free Report) had its target price boosted by Piper Sandler from $145.00 to $153.00 in a research report report published on Wednesday morning, Marketbeat Ratings reports. Piper Sandler currently has an overweight rating on the medical instruments supplier's stock.

Several other equities research analysts have also recently issued reports on ICUI. Wall Street Zen upgraded ICU Medical from a "hold" rating to a "buy" rating in a report on Friday, September 5th. Raymond James Financial lowered their price objective on ICU Medical from $187.00 to $180.00 and set a "strong-buy" rating on the stock in a report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Buy" and an average price target of $181.00.

ICU Medical Price Performance

ICUI stock traded up $0.47 during trading on Wednesday, hitting $130.85. The stock had a trading volume of 83,887 shares, compared to its average volume of 267,706. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.44 and a quick ratio of 1.17. ICU Medical has a twelve month low of $107.00 and a twelve month high of $196.26. The stock has a market capitalization of $3.23 billion, a P/E ratio of -86.37 and a beta of 0.86. The company's 50-day moving average price is $126.23 and its two-hundred day moving average price is $133.60.

ICU Medical (NASDAQ:ICUI - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.44 by $0.66. ICU Medical had a positive return on equity of 7.24% and a negative net margin of 1.56%.The company had revenue of $543.57 million for the quarter, compared to analysts' expectations of $543.33 million. During the same period in the previous year, the firm posted $1.56 EPS. ICU Medical's revenue was down 8.0% compared to the same quarter last year. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. As a group, research analysts predict that ICU Medical will post 4.11 EPS for the current fiscal year.

Insider Buying and Selling at ICU Medical

In other ICU Medical news, CEO Vivek Jain bought 21,929 shares of the company's stock in a transaction that occurred on Thursday, August 14th. The shares were purchased at an average price of $112.84 per share, with a total value of $2,474,468.36. Following the completion of the acquisition, the chief executive officer directly owned 130,149 shares of the company's stock, valued at $14,686,013.16. This represents a 20.26% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David C. Greenberg bought 1,200 shares of the company's stock in a transaction that occurred on Wednesday, August 27th. The stock was acquired at an average cost of $126.42 per share, for a total transaction of $151,704.00. Following the acquisition, the director directly owned 7,960 shares of the company's stock, valued at $1,006,303.20. The trade was a 17.75% increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 1.50% of the company's stock.

Hedge Funds Weigh In On ICU Medical

Large investors have recently bought and sold shares of the stock. GAMMA Investing LLC boosted its stake in ICU Medical by 27.2% in the first quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier's stock valued at $99,000 after acquiring an additional 153 shares in the last quarter. SG Americas Securities LLC acquired a new position in ICU Medical in the first quarter valued at $859,000. Vontobel Holding Ltd. acquired a new position in ICU Medical in the first quarter valued at $235,000. EP Wealth Advisors LLC acquired a new position in ICU Medical in the first quarter valued at $479,000. Finally, Envestnet Asset Management Inc. boosted its stake in ICU Medical by 8.2% in the first quarter. Envestnet Asset Management Inc. now owns 20,269 shares of the medical instruments supplier's stock valued at $2,815,000 after acquiring an additional 1,534 shares in the last quarter. Institutional investors and hedge funds own 96.10% of the company's stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.